CN102038915B - Traditional Chinese medicament for treating hysteromyoma and preparation method thereof - Google Patents
Traditional Chinese medicament for treating hysteromyoma and preparation method thereof Download PDFInfo
- Publication number
- CN102038915B CN102038915B CN2010105675081A CN201010567508A CN102038915B CN 102038915 B CN102038915 B CN 102038915B CN 2010105675081 A CN2010105675081 A CN 2010105675081A CN 201010567508 A CN201010567508 A CN 201010567508A CN 102038915 B CN102038915 B CN 102038915B
- Authority
- CN
- China
- Prior art keywords
- parts
- hysteromyoma
- radix
- filtrating
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicament for treating hysteromyoma and a preparation method thereof. The compound consists of marsdenia tenacissima, nutgrass galingale rhizome, ground beetle, immature bitter orange, common burreed rubber, curcuma zedoary, salvia, medicinal cyathula root, motherwort, safflower, myrrh, giant knotweed rhizome, seaweed, radix notoginseng, moderate asiabell root, astragalus mongholicus, Chinese clematis root, poria, dandelion and liquorice, wherein after the medicaments are decocted or extracted to prepare extract, proper auxiliary materials are added to prepare capsules, particles, tablets, powder, oral solutions and other oral preparations. Clinical and pharmacodynamical test results prove that: the traditional Chinese medicament for treating the hysteromyoma has the functions of reinforcing within dissipation, circulating within elimination, clearing within promotion, invigorating blood circulation without injuring body, reinforcing body without stasis, is safe to treat the hysteromyoma with accurate curative effect, can effectively prevent endocrine disorder caused by hysterectomy, prolepsis of coronary heart disease, climacteric syndrome, osteoporosis and other diseases, occurrence of stump carcinoma of the cervix and the like, provides reliable and advantageous approach for conservative treatment of the hysteromyoma, and has wide market prospect and application prospect.
Description
Technical field
The present invention relates to a kind of Chinese medicine of treating hysteromyoma and preparation method thereof, belong to biological technical field.
Background technology
Hysteromyoma is a sexual maturity female sex organ most common tumor, and its clinical onset rate is 20～25%, and actual incidence rate is up to 40%.Though hysteromyoma is a benign tumor, can bring many miseries to the patient, their physical and mental health in serious harm, so need active treatment.
In the modern medicine, the topmost method and the most frequently used means of treatment hysteromyoma are excisions.Although along with the progress of medical science, operative treatment has developed various ways, but still respectively deposits drawback.Can cause endocrine regulation like uterectomy, diseases such as coronary heart disease, climacteric syndrome, osteoporosis are taken place ahead of time; Ablation has the possibility of bringing out the cervix uteri stump cancer, and can cause the distortion in uterus and the change of 26S Proteasome Structure and Function; The relapse rate of muscular tumor enucleation is higher.
The expectant treatment of hysteromyoma more and more comes into one's own.Though the maximum non-surgical treatment of clinical research in recent years is a UAE; But side reactions such as this therapy often causes the pelvic cavity avascular pain, feels sick, heating also can cause complication such as suppurative endometritis, tumor infarction, the irreversible necrosis in uterus.Also have several kinds of new Therapeutic Method, like anhydrous alcohol injection, micro-wave therapeutic, radiotherapy etc. in heat radiofrequency ablation, the tumor, but clinical report is few, and late result still under observation.So medicine is still very important to the treatment of hysteromyoma.
Mostly the Western medicine of the treatment hysteromyoma of present clinical use is hormone medicine, and like danazol and GnRH analog, though can temporarily dwindle muscular tumor, muscular tumor can be grown up once again after the drug withdrawal, and the life-time service side effect is obvious.Also there is multiple compound preparation to be used to alleviate the symptom that hysteromyoma causes in the Chinese medicine, but how do not have the effect that the muscular tumor of making is dwindled, patient often occurs and take Chinese medicine for a long time, but the phenomenon of having to have an operation at last.
In a word, at present in the Drug therapy of hysteromyoma, in, doctor trained in Western medicine all do not have satisfied square medicine.If can develop and a kind ofly can definitely dwindle hysteromyoma and the little medicine of side effect, vast market prospect and application prospect will be arranged.
Summary of the invention
The object of the present invention is to provide a kind of to the treatment hysteromyoma Chinese medicine of definite curative effect and preparation method thereof is arranged.
The present invention is to provide a kind of like this Chinese medicine of treating hysteromyoma, it is made up of the crude drug of following mass parts:
230～250 parts of Caulis Marsdeniae Tenacissimaes, 400～430 parts of Rhizoma Cyperis, 160～200 parts of Eupolyphaga Seu Steleophagas,
100～120 parts of Fructus Aurantii Immaturuss, triangular 160～200 parts, 160～200 parts of Rhizoma Curcumae,
160～200 parts of Radix Salviae Miltiorrhizaes, 160～200 parts of Radix Cyathulaes, 95～110 parts of Herba Leonuris,
40～80 parts on Flos Carthami, 70～100 parts of Myrrhas, 160～200 parts of Rhizoma Polygoni Cuspidati,
120～160 parts of Sargassums, 50～80 parts of Radix Notoginseng, 70～110 parts of Radix Codonopsis,
100～150 parts of the Radixs Astragali, 100～150 parts of Radix Clematidis, 160～200 parts in Poria,
70～110 parts of Herba Taraxacis, 30～40 parts in Radix Glycyrrhizae.
The traditional Chinese medicine in order Cyperus liver qi stagnation, qi pain, expelling Eupolyphaga eliminate disease, through the meridians King and medicine; aurantium broken gas line to stagnation, Curcuma expelling gas line, salvia, Chuan Niu knee, saffron, myrrh synergies, stasis, seaweed Endometriosis drugs for the minister; accompanied thirty-seven stasis to stop bleeding, blood and pain, Codonopsis, Astragalus taken blood, bleeding went without bleeding the disadvantages; clearance vine, clematis meridian, Xiaoyu swollen; dandelion, knotweed, motherwort has detoxification of reactive power, can clear solution of bleeding of the uterus Kurume toxic heat, but also for the benefit of both wet With effect; Poria dampness phlegm, to help eliminate disease purposes, licorice reconcile the various drugs.All medicine compatibilities have benefit in loosing, and in disappearing row are arranged, and have in the profit clearly, invigorate blood circulation and just do not hinder, and set upright and do not stay the stasis of blood.The clinical hysteromyoma that is used to treat caused by energy stagnation and blood stasis, determined curative effect is not seen toxicity.
The Chinese medicine of the above-mentioned prescription of treatment hysteromyoma according to the invention is taken behind the fried one-tenth decoction of Direct Water.
The Chinese medicine of the above-mentioned prescription of treatment hysteromyoma according to the invention; Behind conventional water extraction or ethanol extraction; Filter to isolate filtrating and filtering residue through routine; Filtrating after routine concentrates, is dried to dry extract, allocate suitable adjuvant into by routine after, be prepared into peroral dosage forms such as capsule, granule, tablet, powder or pill again through conventional moulding process.
The present invention is an index with the content of dried cream yield and Caulis Marsdeniae Tenacissimae glycosides H (Tenacissoside H) and danshensu (Danshensu), and adopting the extraction and purification process of the definite crude drug of orthogonal experiment optimization is the following step:
A, said each crude drug pulverized after, decocting extracts three times, each water consumption is 8～12 times of medical material gross mass, each decocting extracts and keeps little boiling 0.5～1.5 hour, merges three times extracting solution, filters to isolate and filtrates and filtering residue;
B, the filtrating of A step is concentrated into 1g medical material/ml, cools off, leaves standstill, stir that slowly to add ethanol to ethanol final concentration down be 60wt% to room temperature, leave standstill to deposition fully, sucking filtration is isolated filtrating and filtering residue;
C, the filtering residue of B step is used mass concentration is 60% washing with alcohol, colourless until cleaning mixture, cleaning mixture is incorporated in the filtrating of B step, reclaims ethanol, and drying is pulverized, and must treat the dry extract of hysteromyoma.
The dry extract of said C step is promptly processed the peroral dosage forms such as capsule, granule, tablet, powder or pill of treating hysteromyoma with after an amount of pharmaceutic adjuvant mixes by conventional moulding process.
High performance liquid chromatogram (HPLC) chromatographic condition of Caulis Marsdeniae Tenacissimae glycosides H assay is in the dry extract of the present invention: chromatographic column uses octadecyl bonding phase silica gel to be filler; Acetonitrile-water (50: 50) is a mobile phase; Flow velocity: 0.8ml/min; Temperature: 35 ℃; Evaporative light scattering detector ELSD parameter: atomization temperature: 80 ℃, air velocity: 1.5ml/min.
The HPLC assay chromatographic condition of danshensu is in the dry extract of the present invention: chromatographic column uses octadecyl bonding phase silica gel to be filler; Mobile phase: 0.9% aqueous acetic acid (containing 5% acetonitrile)-methanol (96: 4); Flow velocity: 0.5ml/min; UV-detector detects wavelength: 280nm; Temperature: 35 ℃.
The dry extract pharmacodynamics evaluation methodology that the present invention treats hysteromyoma is: get the female Kunming mouse of body weight 12-15g, weigh random packet.Give respectively: 0.5%CMC, as negative control group, the 0.2mg/kg diethylstilbestrol, as the modeling group, 20-200mg/kg organizes as the examination that receives of dry extract of the present invention, and the mifepristone of 10mg/kg and the BAIXIAO DAN of 5g/kg are as the positive control medicine.Administering mode: irritate stomach.Administration volume 20ml/kg, continuous 5 days.Mice was weighed once in per two days, and according to body weight adjustment dosage.Mice the last time after the administration 24h weigh, put to death.Take out the uterus, be weighed as the uterus weight in wet base.The uterus is broken, the interior liquid of uterine cavity is flow to end, weigh, be the uterus weight in wet base of anhydrating.Weigh once more behind 80 ℃ of dry 24h then, be the uterus dry weight.The weight in wet base ratio is done in unit of account body weight uterus weight and uterus, and the result is with t check carrying out significance test.Compared with the modeling group by the examination group, the weight in wet base ratio is done in per weight uterus weight or uterus has obvious reduction, shows that promptly dry extract medicine of the present invention is effective.
The present invention is theoretical in conjunction with traditional Chinese medicine, with softening and resolving hard mass, and soothing liver-qi stagnation, regulating qi-flowing for relieving pain, broken blood eliminating mass, clearing and activating the channels and collaterals, relieving stagnant Qi is capable to stagnate, promoting blood circulation, removing blood stasis and hemostasis, the analgesic therapy of invigorating blood circulation, nourishing qi to stop, the network that stimulates the menstrual flow, the stasis of blood that disappears swell; Clearing heat and detoxicating, the dampness removing dissolving phlegm.All medicine compatibilities have benefit in loosing, and in disappearing row are arranged; Have in the profit clearly, invigorate blood circulation and just do not hinder, set upright and do not stay the stasis of blood; To the treatment safety and the determined curative effect of hysteromyoma, the endocrine regulation that effectively prevents uterectomy and brought, the taking place ahead of time and generation of cervix uteri stump cancer or the like of diseases such as coronary heart disease, climacteric syndrome, osteoporosis; For the expectant treatment of hysteromyoma provides reliable, favourable approach, have vast market prospect and application prospect.
The specific embodiment
Below in conjunction with embodiment the present invention is done and to further describe.
Embodiment 1
Get material by following prescription:
240 parts of Caulis Marsdeniae Tenacissimaes, 420 parts of Rhizoma Cyperis, 180 parts of Eupolyphaga Seu Steleophagas,
120 parts of Fructus Aurantii Immaturuss, triangular 180 parts, 180 parts of Rhizoma Curcumae,
180 parts of Radix Salviae Miltiorrhizaes, 180 parts of Radix Cyathulaes, 105 parts of Herba Leonuris,
60 parts on Flos Carthami, 90 parts of Myrrhas, 180 parts of Rhizoma Polygoni Cuspidati,
140 parts of Sargassums, 60 parts of Radix Notoginseng, 90 parts of Radix Codonopsis,
120 parts of the Radixs Astragali, 120 parts of Radix Clematidis, 180 parts in Poria,
90 parts of Herba Taraxacis, 36 parts in Radix Glycyrrhizae;
The following method of process:
A, above-mentioned each crude drug is pulverized, crossed a sieve (10 order), add the hydroecium relaxing the bowels with purgatives of warm nature and soaked 3 hours; Decoct then and extract three times; Each water consumption is heavy 8 times of the total matter of medical material, each decoct to extract keep little boiling 0.5 hour, merge three times extracting solution; Filter with 400 order filter clothes, isolate filtrating and filtering residue.
B, with the filtrating normal pressure of A step down heating be concentrated into 1g medical material/ml; Cool off, leave standstill to room temperature, stir 95% (mass concentration) ethanol that slowly adds 1.7 times of heavy amounts of the total matter of medical material down, making the ethanol final concentration is 60%; Leave standstill to precipitating fully sucking filtration separating filtrate and filtering residue;
C, the filtering residue of B step is used mass concentration is 60% washing with alcohol, colourless until cleaning mixture, cleaning mixture is incorporated in the filtrating of B step, reclaims ethanol, drying, pulverize dry extract.
Repeat embodiment 1 secondary, obtain three parts of dry extracts respectively.Measure content of Danshensu, danshensu total amount, the danshensu rate of transform, TS-H content, TS-H total amount and the TS-H rate of transform in the dried cream yield of three parts of dry extracts of gained, the dried cream, the result shows process repeatability better (table 1).The pharmacodynamic experiment result shows that the dry extract with this prepared has significant inhibitory effect (table 2) to the inductive Mouse Uterus hypertrophy of diethylstilbestrol.
Embodiment 2
Get material by following prescription:
250 parts of Caulis Marsdeniae Tenacissimaes, 400 parts of Rhizoma Cyperis, 200 parts of Eupolyphaga Seu Steleophagas,
120 parts of Fructus Aurantii Immaturuss, triangular 160 parts, 200 parts of Rhizoma Curcumae,
200 parts of Radix Salviae Miltiorrhizaes, 160 parts of Radix Cyathulaes, 110 parts of Herba Leonuris,
80 parts on Flos Carthami, 70 parts of Myrrhas, 160 parts of Rhizoma Polygoni Cuspidati,
160 parts of Sargassums, 50 parts of Radix Notoginseng, 70 parts of Radix Codonopsis,
150 parts of the Radixs Astragali, 100 parts of Radix Clematidis, 160 parts in Poria,
110 parts of Herba Taraxacis, 30 parts in Radix Glycyrrhizae.
The following method of process: above-mentioned each crude drug is pulverized, crossed a sieve (10 order), add the hydroecium relaxing the bowels with purgatives of warm nature and soaked 1 hour; Decoct to extract then three times, each water consumption is heavy 12 times of the total matter of medical material, each decoct to extract keep little boiling 1 hour; Merge three times extracting solution, filter, isolate filtrating and filtering residue with 400 order filter clothes; Filtrating is carried out conventional spray drying, be powder of the present invention.
Results of pharmacodynamic test shows that this powder has the uterus proliferative effect that the inhibition diethylstilbestrol causes, makes the uterus under the stimulation of diethylstilbestrol, can keep normal tissue, moisture ratio (table 3).
Embodiment 3
Get material by following prescription:
230 parts of Caulis Marsdeniae Tenacissimaes, 430 parts of Rhizoma Cyperis, 160 parts of Eupolyphaga Seu Steleophagas,
100 parts of Fructus Aurantii Immaturuss, triangular 200 parts, 160 parts of Rhizoma Curcumae,
160 parts of Radix Salviae Miltiorrhizaes, 200 parts of Radix Cyathulaes, 95 parts of Herba Leonuris,
40 parts on Flos Carthami, 100 parts of Myrrhas, 200 parts of Rhizoma Polygoni Cuspidati,
120 parts of Sargassums, 80 parts of Radix Notoginseng, 110 parts of Radix Codonopsis,
100 parts of the Radixs Astragali, 150 parts of Radix Clematidis, 200 parts in Poria,
70 parts of Herba Taraxacis, 40 parts in Radix Glycyrrhizae;
Through making dry extract (crossing 80 mesh sieves) with embodiment 1 identical method, said dry extract is mixed with the mass ratio of powder microcrystalline Cellulose by 8: 2, grind, cross 80 mesh sieves; Mixing, 20% heavy mass concentration of spray medical material total matter is 90% ethanol system soft material, mistake 40 mesh sieves are processed granule, in 60 ℃ of oven dryings; Granulate gets 40-80 order granule, adds 1% magnesium stearate; Be sub-packed in No. 0 capsule, average loading amount is 0.4g, promptly gets capsule of the present invention.
Embodiment 4
Get material by following prescription:
230 parts of Caulis Marsdeniae Tenacissimaes, 410 parts of Rhizoma Cyperis, 170 parts of Eupolyphaga Seu Steleophagas,
120 parts of Fructus Aurantii Immaturuss, triangular 190 parts, 190 parts of Rhizoma Curcumae,
160 parts of Radix Salviae Miltiorrhizaes, 170 parts of Radix Cyathulaes, 100 parts of Herba Leonuris,
80 parts on Flos Carthami, 80 parts of Myrrhas, 170 parts of Rhizoma Polygoni Cuspidati,
120 parts of Sargassums, 60 parts of Radix Notoginseng, 100 parts of Radix Codonopsis,
150 parts of the Radixs Astragali, 130 parts of Radix Clematidis, 190 parts in Poria,
100 parts of Herba Taraxacis, 35 parts in Radix Glycyrrhizae.
Through making dry extract (crossing 80 mesh sieves) with embodiment 1 identical method; With said dry extract and soluble starch and xylosic alcohol powder by 4: 5: 1.8 quality than uniform mixing, 30% heavy mass concentration of the total matter of spray medical material is 50% ethanol system soft material, crosses the granulation of 12 mesh sieves; 60 ℃ of oven dry; Granulate, packing promptly gets granule of the present invention.
Embodiment 5
Get material by following prescription:
245 parts of Caulis Marsdeniae Tenacissimaes, 415 parts of Rhizoma Cyperis, 172 parts of Eupolyphaga Seu Steleophagas,
111 parts of Fructus Aurantii Immaturuss, triangular 175 parts, 185 parts of Rhizoma Curcumae,
185 parts of Radix Salviae Miltiorrhizaes, 185 parts of Radix Cyathulaes, 98 parts of Herba Leonuris,
68 parts on Flos Carthami, 96 parts of Myrrhas, 178 parts of Rhizoma Polygoni Cuspidati,
155 parts of Sargassums, 75 parts of Radix Notoginseng, 98 parts of Radix Codonopsis,
135 parts of the Radixs Astragali, 145 parts of Radix Clematidis, 186 parts in Poria,
90 parts of Herba Taraxacis, 35 parts in Radix Glycyrrhizae.
Through making dry extract (cross 80 mesh sieves) with embodiment 1 identical method, with said dry extract and sodium carboxymethyl cellulose, starch, microcrystalline Cellulose and polyplasdone XL by 8: 0.5: 0.5: 0.3: 0.4 quality is than uniform mixing, sprays 30% heavy mass concentration of the total matter of medical material and be 50% ethanol system soft material; Pushed 22 eye mesh screens; 60 ℃ of oven dry through 22 orders and 30 mesh sieve granulate, get the granule of 22 orders～30 orders size; Add 3% heavy disintegrating agent polyplasdone XL of the total matter of medical material; Mix homogeneously, tabletting promptly gets tablet of the present invention.
Table 1 crude drug extraction process demonstration test result
Table 3 embodiment 2 prepared powders are to the outgrowth effect in diethylstilbestrol induced mice uterus
X ± SD, compare with the CMC group #P＜0.01;
*P＜0.05,
*Compare with the diethylstilbestrol group P＜0.01
The existing definite curative effect that further specifies the Chinese medicine of treatment hysteromyoma of the present invention through clinical report.
One, a data and method (legitimacy of PLSCONFM clinical experiment, otherwise call trouble together! )
1, physical data
The patient that the hysteromyoma disease is arranged 120 examples through hospital makes a definite diagnosis are divided into two groups at random, and wherein: test group 60 examples, matched group 60 examples (should be three groups! Revise relevant portion), two groups of patients' ordinary circumstance is seen table 4.
Two groups of patients' ordinary circumstance is organized in table 4 matched group and treatment
2, (deletion producer avoids possible lawsuit trouble to Therapeutic Method! )
Matched group is divided into three groups of A, B, C, and every group of each 20 example are taken following commercial medicine respectively:
A group: GUIZHI FULING JIAONANG, three times on the one, one time 3;
The B group: the palace tumor disappears, and three times on the one, a 3-4 grain
C group: BAIXIAO DAN, twice, one time on the one 10 balls
Test group is taken the Chinese medicine of the present invention's embodiment 1, and three times on the one, each 4-6 grain is all used a small amount of warm water delivery service at every turn.
All take, and during treating, cut out other related drugs for two groups by identical 8 weeks of the course of treatment.
3, observational technique
Period in a medicine is observed weekly once, comprises symptom, sign improvement situation, untoward reaction.The pressure of having a blood test respectively before and after the treatment is looked into heart, liver, renal function and routine urinalysis.Treatment finishes to check B ultrasonic by the special messenger in two weeks, observes the size variation situation of muscular tumor.
Two, curative effect judgment criteria
1, criterion of therapeutical effect
According to the criterion of therapeutical effect of Ministry of Public Health bureau of drug administration about " the clinical research guideline of new drug (Chinese medicine) treatment muscular tumor ", " new drug (Chinese medicine) treatment hysteromyoma disease clinical research guideline ".
Cure: the muscular tumor complete obiteration, inflammation is eliminated, no pain;
Produce effects: muscular tumor reduces more than 50%, and inflammation is eliminated, no pain;
Effectively: muscular tumor reduces less than 50%, NIP, pain relief;
Invalid: muscular tumor constant (mainly being the lenticular calculus), still have inflammation, radiated pain still takes place.
2, statistical method
Enumeration data adopts ultrasound diagnosis
Total effective rate=cure rate+obvious effective rate+effective percentage
Three, result
2, B ultrasonic observation hysteromyoma curative effect is seen table 2.
Table 5 hysteromyoma curative effect situation (120 example)
Treatment group curative effect obviously is superior to matched group.Matched group should be divided into A in this form, B, and C lists respectively for three groups!
3, untoward reaction
Treatment group patient has no adverse reaction.
4, this medicine clinical indication has:
Anti-uterus carcinoma, hydatidiform mole, ovarian cyst, endometrial polyp, cervical erosion, adnexitis, metrorrhagia, obstruction of fallopian tube, dysmenorrhea; Cyclomastopathy; Chloasma, mottle; Climacteric syndrome.This medicine all has significant curative effect to above-mentioned disease, and cure rate is high.
Four, discuss
The present invention is the pure natural Chinese herbal and crude drugs preparations, and it collects the Lahu, the disappear elite of knurl side of the Dai Nationality, each family of national medicines such as Was; Through research and the clinical observation of two more than ten years, theoretical in conjunction with traditional Chinese medicine, with softening and resolving hard mass, soothing liver-qi stagnation, regulating qi-flowing for relieving pain; Broken blood eliminating mass, clearing and activating the channels and collaterals, relieving stagnant Qi is capable to stagnate promoting blood circulation, removing blood stasis and hemostasis; The analgesic therapy of invigorating blood circulation, nourishing qi to stop, the network that stimulates the menstrual flow, the stasis of blood that disappears are swollen; Clearing heat and detoxicating, the dampness removing dissolving phlegm.All medicine compatibilities have benefit in loosing, and in disappearing row are arranged, and have in the profit clearly, invigorate blood circulation and just do not hinder, and set upright and do not stay the stasis of blood.The clinical hysteromyoma that is used to treat caused by energy stagnation and blood stasis, determined curative effect is not seen toxicity.
Claims (3)
1. Chinese medicine of treating hysteromyoma, it is made up of the crude drug of following mass parts:
230～250 parts of Caulis Marsdeniae Tenacissimaes, 400～430 parts of Rhizoma Cyperis, 160～200 parts of Eupolyphaga Seu Steleophagas,
100～120 parts of Fructus Aurantii Immaturuss, triangular 160～200 parts, 160～200 parts of Rhizoma Curcumae,
160～200 parts of Radix Salviae Miltiorrhizaes, 160～200 parts of Radix Cyathulaes, 95～110 parts of Herba Leonuris,
40～80 parts on Flos Carthami, 70～100 parts of Myrrhas, 160～200 parts of Rhizoma Polygoni Cuspidati,
120～160 parts of Sargassums, 50～80 parts of Radix Notoginseng, 70～110 parts of Radix Codonopsis,
100～150 parts of the Radixs Astragali, 100～150 parts of Radix Clematidis, 160～200 parts in Poria,
70～110 parts of Herba Taraxacis, 30～40 parts in Radix Glycyrrhizae.
2. the preparation method of Chinese medicine of treatment hysteromyoma as claimed in claim 1 is characterized in that crude drug process following steps:
A, said each crude drug pulverized after, decocting extracts three times, each water consumption is 8～12 times of medical material gross mass, each decocting extracts and keeps little boiling 0.5～1.5 hour, merges three times extracting solution, filters to isolate and filtrates and filtering residue;
B, the filtrating of A step is concentrated into 1g medical material/ml, cools off, leaves standstill, stir that slowly to add ethanol to ethanol final concentration down be 60wt% to room temperature, leave standstill to deposition fully, sucking filtration is isolated filtrating and filtering residue;
C, the filtering residue of B step is used mass concentration is 60% washing with alcohol, colourless until cleaning mixture, cleaning mixture is incorporated in the filtrating of B step, reclaims ethanol, and drying is pulverized, and must treat the dry extract of hysteromyoma.
3. method as claimed in claim 2 after it is characterized in that the dry extract of said C step and pharmaceutic adjuvant mixing in right amount, is promptly processed capsule, granule, tablet, powder or the pill of treatment hysteromyoma by conventional moulding process.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105675081A CN102038915B (en) | 2010-12-01 | 2010-12-01 | Traditional Chinese medicament for treating hysteromyoma and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105675081A CN102038915B (en) | 2010-12-01 | 2010-12-01 | Traditional Chinese medicament for treating hysteromyoma and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102038915A CN102038915A (en) | 2011-05-04 |
| CN102038915B true CN102038915B (en) | 2012-05-30 |
Family
ID=43905676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105675081A Active CN102038915B (en) | 2010-12-01 | 2010-12-01 | Traditional Chinese medicament for treating hysteromyoma and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102038915B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102935204B (en) * | 2012-11-27 | 2014-02-12 | 王兆霞 | Traditional Chinese medicine preparation for treating hysteromyoma |
| CN103656529B (en) * | 2013-12-23 | 2015-10-28 | 傅晓倩 | One treats cirsoid External-applicationtraditional traditional Chinese medicinal |
| CN104208183A (en) * | 2014-09-12 | 2014-12-17 | 广西中医药大学 | Externally used Yao medicine composition for treating cystic hyperplasia of breasts and preparation method thereof |
| CN105749166A (en) * | 2016-04-12 | 2016-07-13 | 刘昌红 | Traditional Chinese medicine composition for treating uterine fibroid |
| CN112268968B (en) * | 2020-10-16 | 2022-05-10 | 山东步长神州制药有限公司 | Detection method of fingerprint spectrum of medicinal preparation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1613481A (en) * | 2003-11-09 | 2005-05-11 | 黄双元 | Chinese patent drug for treating female ovarian cyst and its preparation |
| CN101711849A (en) * | 2009-10-26 | 2010-05-26 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating symptoms of qi stasis, blood stasis, myoma and cyst and preparation method |
-
2010
- 2010-12-01 CN CN2010105675081A patent/CN102038915B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1613481A (en) * | 2003-11-09 | 2005-05-11 | 黄双元 | Chinese patent drug for treating female ovarian cyst and its preparation |
| CN101711849A (en) * | 2009-10-26 | 2010-05-26 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating symptoms of qi stasis, blood stasis, myoma and cyst and preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 翟春杰等.子宫肌瘤的中医药治疗进展.《光明中医》.2009,(第11期), * |
| 霍素芬等.子宫肌瘤的中医治疗进展.《辽宁中医药大学学报》.2008,(第01期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102038915A (en) | 2011-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102716417B (en) | Traditional Chinese medicine preparation for treating gynaecopathia and preparation method of preparation | |
| US20060141071A1 (en) | Compositions and methods for treating gynecological disorders | |
| CN102000175B (en) | Traditional Chinese medicine composition for treating hemorrhoids and preparation method thereof | |
| CN102038915B (en) | Traditional Chinese medicament for treating hysteromyoma and preparation method thereof | |
| CN101780160B (en) | Traditional Chinese medicine preparation for treating gynecological disease and preparation method thereof | |
| CN102698031B (en) | Yougui capsule and preparation method thereof | |
| CN101897821B (en) | Granular preparation for promoting blood circulation, dredging collaterals and relieving pain and preparation method as well as detection method thereof | |
| CN101214315B (en) | Medicament for preventing and treating gynaecologic hemorrhage and preparation thereof | |
| CN103169831B (en) | Traditional Chinese medicine composition for treating dysmenorrhea and preparation method thereof | |
| CN102225145A (en) | Traditional Chinese medicine oral liquid for treating hysteromyoma and preparation method thereof | |
| CN100371012C (en) | Medicinal composition, and its preparing method and use | |
| CN103432419A (en) | Traditional Chinese medicinal composition for treating dysfunctional uterine bleeding and preparation method of preparation thereof | |
| CN103285330A (en) | Traditional Chinese medicine for treating uterine fibroid and preparation method thereof | |
| CN102343019B (en) | Chinese medicinal composition for treating amenorrhea and preparation method of preparation thereof | |
| CN100566706C (en) | A kind of Chinese medicinal capsule for the treatment of cyclomastopathy and preparation method thereof | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN102145152B (en) | Tradition Chinese medicinal preparation for treating cyclomastopathy and preparation method thereof | |
| CN103127272A (en) | Chinese medicinal preparation for treating breast disease and preparation method thereof | |
| CN106237181A (en) | A kind of Chinese medicine composition treating rheumatoid arthritis and capsule thereof and preparation method | |
| CN102198251B (en) | Chinese medicinal composition for treating climacteric syndrome and preparation method thereof | |
| CN1733197B (en) | Medicine for curing chronic prostatitis and process for preparing the same | |
| CN104491670A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease | |
| CN101822800B (en) | Medicine composite for treating breast disease and preparation method thereof | |
| CN110859945B (en) | Capsule for preventing and treating ankylosing spondylitis and preparation method thereof | |
| CN101961481A (en) | Traditional Chinese medicine for treating liver-gallbladder qi stagnation type cholecystitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |